pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

Table 4 TP53 mutation analysis [exon 5–8] in 12 selected good- and poor-risk study patients from AIO-PK0104 (in correlation with KRAS status and p53 IHC)

Case	Exon 5	Exon 6	Exon 7	Exon 8	p53 expression by IHC	KRAS status (Exon 2)	Best response by imaging (RECIST)	TTF1 [Mo.]
198	wt	wt	wt	wt	regular	wt	PR	19.1
8	n.a.	n.a.	R249S	n.a.	n.a.	mut	SD	6.0
197	n.a.	wt	n.a.	wt	Regular	mut	PD	1.8
60	n.a.	wt	n.a.	wt	n.a.	mut	PR	6.3
89	wt	wt	wt	wt	n.a.	wt	SD	9.8
64	wt	wt	wt	wt	n.a.	mut	SD	10.0
50	n.a.	D208N	wt	wt	n.a.	mut	PD	2.0
33	n.a.	wt	R248R*	wt	n.a.	mut	SD	19.6
134	V147I	wt	wt	wt	Overexpression	mut	SD	3.9
132	n.a.	wt	wt	V274I	Overexpression	mut	PD	2.2
99	T155I &	wt	wt	wt	n.a.	mut	PD	0.5
	V137M
98	wt	wt	wt	wt	n.a.	wt	PD	1.7

Abbreviations: IHC Immunohistochemistry, Mo Months, mut Mutation, PD Progressive disease, PR Partial response, SD Stable disease, TTF1 Time-to-treatment failure after 1^st-line therapy, wt Wildtype.
(*silent mutation).

ISSN: 1471-2407